Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

a-s medication solutions - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - ketorolac tromethamine  ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.  ketorolac tromethamine ophthalmic solution is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formulation [see adverse reactions (6.1) ] . risk summary there are no adequate or well-controlled studies with ketorolac tromethamine ophthalmic solution in pregnant women. no evidence of teratogenicity has been observed in rats or rabbits with ketorolac tromethamine ophthalmic solution at clinically relevant doses. risk summary it is not known whether ketorolac when given topically is present in human milk. because many drugs are excreted in human milk, caution should be exercised when ketorolac tromethamine ophthalmic solution is administered to a nursing woman. safety and effectiveness of ketorolac tromethamine in pediatric patients below the age of 3 have not been established. no overall differences in safety or effectiveness have been observed between elderly and other adult patients.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - cefadroxil (unii: 280111g160) (cefadroxil anhydrous - unii:q525pa8jjb) - cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: urinary tract infections caused by e. coli, p. mirabilis, and klebsiella species. skin and skin structure infections caused by staphylococci and/or streptococci. pharyngitis and/or tonsillitis caused by streptococcus pyogenes (group a beta-hemolytic streptococci). note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefadroxil is generally effective in the eradication of streptococci from the oropharynx.  however, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. note: culture and susceptibility tests should be initiated prior to and during therapy.  renal function studies should be performed when indicated. to reduce the development of drug-resistant bacteria and maintain t

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

woodward pharma services llc - naproxen (unii: 57y76r9atq) (naproxen - unii:57y76r9atq) - naproxen tablets, ec-naproxen, and naproxen sodium are indicated for: the relief of the signs and symptoms of: - rheumatoid arthritis - osteoarthritis - ankylosing spondylitis - polyarticular juvenile idiopathic arthritis naproxen tablets and naproxen sodium are also indicated for: the relief of signs and symptoms of: - tendonitis - bursitis - acute gout the management of: - pain - primary dysmenorrhea naproxen tablets, ec-naproxen, and naproxen sodium are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [see warnings and precautions (5.7, 5.9)]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8)] . - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions ( 5.1)] . risk summary use of nsaids, including naproxen tablets, ec-naproxen, and naproxen sodium, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. because of these risks, limit dose and duration of naproxen tablets, ec-naproxen, or naproxen sodium use between about 20 and 30 weeks of gestation, and avoid naproxen tablets, ec-naproxen, and naproxen sodium use at about 30 weeks of gestation and later in pregnancy [see clinical considerations, data]. premature closure of fetal ductus arteriosus: use of nsaids, including naproxen tablets, ec-naproxen, and naproxen sodium, at about 30 weeks gestation or later in pregnancy increases the risk of premature closure of the fetal ductus arteriosus. oligohydramnios/neonatal renal impairment: use of nsaids at about 20 weeks gestation or later in pregnancy has been associated with cases of fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment. data from observational studies regarding potential embryofetal risks of nsaid use in women in the first or second trimesters of pregnancy are inconclusive. in the general u.s. population, a l clinica ly recognized pregnancies, regardless of drug exposure, have a background rate of 2-4% for major malformations, and 15-20% for pregnancy loss. in animal reproduction studies in rats, rabbits, and mice no evidence of teratogenicity or fetal harm when naproxen was administered during the period of organogenesis at doses 0.13, 0.26, and 0.6 times the maximum recommended human daily dose of 1500 mg/day, respectively [see data] . based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization. in animal studies, administration of prostaglandin synthesis inhibitors such as naproxen, resulted in increased pre- and post-implantation loss. prostaglandins also have been shown to have an important role in fetal kidney development. in published animal studies, prostaglandin synthesis inhibitors have been reported to impair kidney development when administered at clinically relevant doses. the estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. clinical considerations fetal/neonatal adverse reactions premature closure of fetal ductus arteriosus: avoid use of nsaids in women at about 30 weeks gestation and later in pregnancy, because nsaids, including naproxen tablets, ec-naproxen, and naproxen sodium, can cause premature closure of the fetal ductus arteriosus [see data]. oligohydramnios/neonatal renal impairment: if an nsaid is necessary at about 20 weeks gestation or later in pregnancy, limit the use to the lowest effective dose and shortest duration possible. if naproxen tablets, ec-naproxen, or naproxen sodium treatment extends beyond 48 hours, consider monitoring with ultrasound for oligohydramnios. if oligohydramnios occurs, discontinue naproxen tablets, ec-naproxen, and naproxen sodium, and follow up according to clinical practice [see data]. labor or delivery there are no studies on the effects of naproxen tablets, ec-naproxen, or naproxen sodium during labor or delivery. in animal studies, nsaids, including naproxen, inhibit prostaglandin synthesis, cause delayed parturition, and increase the incidence of stillbirth. data human data there is some evidence to suggest that when inhibitors of prostaglandin synthesis are used to delay preterm labor, there is an increased risk of neonatal complications such as necrotizing enterocolitis, patent ductus arteriosus, and intracranial hemorrhage. naproxen treatment given in late pregnancy to delay parturition has been associated with persistent pulmonary hypertension, renal dysfunction, and abnormal prostaglandin e levels in preterm infants. because of the known effects of nonsteroidal anti- inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy (particularly starting at 30-weeks of gestation, or third trimester) should be avoided. premature closure of fetal ductus arteriosus published literature reports that the use of nsaids at about 30 weeks of gestation and later in pregnancy may cause premature closure of the fetal ductus arteriosus. oligohydramnios/neonatal renal impairment: published studies and postmarketing reports describe maternal nsaid use at about 20 weeks gestation or later in pregnancy associated with fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment. these adverse outcomes are seen, on average, after days to weeks of treatment,although oligohydramnios has been infrequently reported as soon as 48 hours after nsaid initiation. in many cases, but not all, the decrease in amniotic fluid was transient and reversible with cessation of the drug. there have been a limited number of case reports of maternal nsaid use and neonatal renal dysfunction without oligohydramnios, some of which were irreversible. some cases of neonatal renal dysfunction required treatment with invasive procedures, such as exchange transfusion or dialysis. methodological limitations of these postmarketing studies and reports include lack of a control group; limited information regarding dose, duration, and timing of drug exposure; and concomitant use of other medications.these limitations preclude establishing a reliable estimate of the risk of adverse fetal and neonatal outcomes with maternal nsaid use. because the published safety data on neonatal outcomes involved mostly preterm infants, the generalizability of certain reported risks to the full-term infant exposed to nsaids through maternal use is uncertain. animal data reproduction studies have been performed in rats at 20 mg/kg/day (0.13 times the maximum recommended human daily dose of 1500 mg/day based on body surface area comparison), rabbits at 20 mg/kg/day (0.26 times the maximum recommended human daily dose, based on body surface area comparison), and mice at 170 mg/kg/day (0.6 times the maximum recommended human daily dose based on body surface area comparison) with no evidence of impaired fertility or harm to the fetus due to the drug. risk summary the naproxen anion has been found in the milk of lactating women at a concentration equivalent to approximately 1% of maximum naproxen concentration in plasma. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for naproxen tablets, ec-naproxen, or naproxen sodium and any potential adverse effects on the breastfed infant from the naproxen tablets, ec-naproxen, or naproxen sodium or from the underlying maternal condition. infertility females based on the mechanism of action, the use of prostaglandin-mediated nsaids, including naproxen tablets, ec-naproxen, and naproxen sodium, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women. published animal studies have shown that administration of prostaglandin synthesis inhibitors has the potential to disrupt prostaglandin-mediated follicular rupture required for ovulation. small studies in women treated with nsaids have also shown a reversible delay in ovulation. consider withdrawal of nsaids, including naproxen tablets, ec-naproxen and naproxen sodium, in women who have difficulties conceiving or who are undergoing investigation of infertility. safety and effectiveness in pediatric patients below the age of 2 years have not been established. pediatric dosing recommendations for polyarticular juvenile idiopathic arthritis are based on well-controlled studies [ see dosage and administration (2) ]. there are no adequate effectiveness or dose-response data for other pediatric conditions, but the experience in polyarticular juvenile idiopathic arthritis and other use experience have established that single doses of 2.5 to 5 mg/kg as naproxen suspension, with total daily dose not exceeding 15 mg/kg/day, are well tolerated in pediatric patients over 2 years of age. the hepatic and renal tolerability of long-term naproxen administration was studied in two double-blind clinical trials involving 586 patients. of the patients studied, 98 patients were age 65 and older and 10 of the 98 patients were age 75 and older. naproxen was administered at doses of 375 mg twice daily or 750 mg twice daily for up to 6 months. transient abnormalities of laboratory tests assessing hepatic and renal function were noted in some patients, although there were no differences noted in the occurrence of abnormal values among different age groups. elderly patients, compared to younger patients, are at greater risk for nsaid-associated serious cardiovascular, gastrointestinal, and/or renal adverse reactions. if the anticipated benefit for the elderly patient outweighs these potential risks, start dosing at the low end of the dosing range, and monitor patients for adverse effects [ see warnings and precautions (5.1, 5.2, 5.3, 5.6, 5.14) ]. studies indicate that although total plasma concentration of naproxen is unchanged, the unbound plasma fraction of naproxen is increased in the elderly. the clinical significance of this finding is unclear, although it is possible that the increase in free naproxen concentration could be associated with an increase in the rate of adverse events per a given dosage in some elderly patients. caution is advised when high doses are required and some adjustment of dosage may be required in elderly patients. as with other drugs used in the elderly, it is prudent to use the lowest effective dose. experience indicates that geriatric patients may be particularly sensitive to certain adverse effects of nonsteroidal anti-inflammatory drugs. elderly or debilitated patients seem to tolerate peptic ulceration or bleeding less well when these events do occur. most spontaneous reports of fatal gi events are in the geriatric population [ see warnings and precautions (5.2) ]. naproxen is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [ see clinical pharmacology (12.3) ]. geriatric patients may be at a greater risk for the development of a form of renal toxicity precipitated by reduced prostaglandin formation during administration of nonsteroidal anti-inflammatory drugs [ see warnings and precautions (5.6) ]. caution is advised when high doses are required and some adjustment of dosage may be required in these patients. it is prudent to use the lowest effective dose [ see clinical pharmacology (12.3) ]. naproxen-containing products are not recommended for use in patients with moderate to severe and severe renal impairment (creatinine clearance <30 ml/min) [ see warnings and precautions (5.6), clinical pharmacology (12.3) ].

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

vetone - ivermectin (unii: 8883yp2r6d) (ivermectin - unii:8883yp2r6d), clorsulon (unii: eg1zdo6lrd) (clorsulon - unii:eg1zdo6lrd) - indications: vetrimec™ plus is indicated for the effective treatment and control of the following parasites in cattle: gastrointestinal roundworms (adults and fourth-stage larvae): ostertagia ostertagi (including inhibited o. ostertagi ) o. lyrata haemonchus placei trichostrongylus axei t. colubriformis cooperia oncophora c. punctata c. pectinata bunostomum phlebotomum nematodirus helvetianus (adults only) n. spathiger (adults only) oesophagostomum radiatum lungworms (adults and fourth-stage larvae): dictyocaulus viviparus liver flukes: fasciola hepatica (adults only) cattle grubs (parasitic stages): hypoderma bovis h. lineatum sucking lice: linognathus vituli haematopinus eurysternus solenopotes capillatus mange mites (cattle scab*): psoroptes ovis (syn. p. communis var. bovis ) sarcoptes scabiei var. bovis persistent activity: ivermectin and clorsulon injection has been proved to effectively control infections and to protect cattle from reinfection with dictyocaulus viviparus and

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

solco healthcare llc - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. in more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such p

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide lotion is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. desonide lotion is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

kmm pharmaceuticals, llc - selenium sulfide (unii: z69d9e381q) (selenium sulfide - unii:z69d9e381q) - this product is a liquid antiseborrheic, antifungal preparation useful for the treatment of seborrheic dermatitis of the scalp, dandruff and tinea versicolor. urea hydrates and is useful for conditions such as dry scalp. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

aurobindo pharma limited - ampicillin trihydrate (unii: hxq6a1n7r6) (ampicillin - unii:7c782967rd) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin capsules and other antibacterial drugs, ampicillin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. in the absence of such data, local epidemiology and susceptibility patterns contribute to the empiric selection of therapy. ampicillin capsules are indicated in the treatment of infections caused by susceptible strains of the designated organisms listed below: infections of the genitourinary tract including gonorrhea: e. coli, p. mirabilis, enterococci, shigella, s. typhosa and other salmonella , and non-penicillinase producing n. gonorrhoeae . infections of the respiratory tract: nonpenicillinase- producing h. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . infections of the gastrointestinal tract: shigella, s. typhosa and other salmonella, e. coli, p. mirabilis, and enterococci. meningitis: n . meningitides . bacteriology studies to determine the causative organisms and their susceptibility to ampicillin capsules should be performed. therapy may be instituted prior to the results of susceptibility testing. a history of a previous hypersensitivity reaction to any of the penicillins is a contraindication. ampicillin is also contraindicated in infections caused by penicillinase-producing organisms.

Jungtiniai Arabų Emyratai - anglų - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

lunatus drug store llc italy - 56’s (14’s blister x 4) - tablet - 550 mg/tablet - infections-antibacterial

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

laboratorios cero s.a. - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - zinc oxide 4.9 g in 100 g - skin protectant uses: helps treat and prevent diaper rash. - protects chafed skin due to diaper rash and helps seal out wetness. stop use and ask a doctor if - condition worsens - symptoms last more than 7 days or clear up and occur again within a few days.